Furthermore, Paiva et al. [40] highlighted PD-L1 upregulation in patients with minimal residual disease (MRD), suggesting that residual PD-L1+ myeloma cells have an increased ability to survive and escape immunosurveillance. The gene discussed is CD274; the disease is plasma cell myeloma.